Gastroparesis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Gastroparesis - Pipeline Review, H1 2015', provides an overview of the Gastroparesis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroparesis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Gastroparesis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gastroparesis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Gastroparesis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Gastroparesis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Gastroparesis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Gastroparesis Overview 6 Therapeutics Development 7 Pipeline Products for Gastroparesis - Overview 7 Pipeline Products for Gastroparesis - Comparative Analysis 8 Gastroparesis - Therapeutics under Development by Companies 9 Gastroparesis - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Gastroparesis - Products under Development by Companies 13 Gastroparesis - Companies Involved in Therapeutics Development 14 GlaxoSmithKline plc 14 RaQualia Pharma Inc. 15 Gastroparesis - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 22 Drug Profiles 23 camicinal - Drug Profile 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 ETX-101 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 NG-101 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 RQ-00000010 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 RQ-00201894 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 velusetrag - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Gastroparesis - Recent Pipeline Updates 30 Gastroparesis - Dormant Projects 33 Gastroparesis - Product Development Milestones 34 Featured News & Press Releases 34 Jan 07, 2014: RaQualia Receives a Patent Allowance for Motilin Receptor Agonist in the USA 34 Jan 08, 2013: Theravance And Alfa Wassermann Announce Initiation Of Phase II Study With Velusetrag For Gastroparesis 34 Sep 14, 2012: RaQualia Pharma's Motilin Receptor Agonist RQ-00201894 Advances To Pre-clinical Stage 34 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37
List of Tables Number of Products under Development for Gastroparesis, H1 2015 7 Number of Products under Development for Gastroparesis - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Gastroparesis - Pipeline by GlaxoSmithKline plc, H1 2015 14 Gastroparesis - Pipeline by RaQualia Pharma Inc., H1 2015 15 Assessment by Monotherapy Products, H1 2015 16 Number of Products by Stage and Target, H1 2015 18 Number of Products by Stage and Mechanism of Action, H1 2015 20 Number of Products by Stage and Route of Administration, H1 2015 21 Number of Products by Stage and Molecule Type, H1 2015 22 Gastroparesis Therapeutics - Recent Pipeline Updates, H1 2015 30 Gastroparesis - Dormant Projects, H1 2015 33
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.